• This document covers elective EVAR performed between 1996-09-19 and 2019-12-19 for abdominal aortic aneurysms
  • ie. common iliac artery aneurysms are excluded as well as symptomatic AAAs, ruptures etc.
  • This comprises 937 elective EVAR

1 Iliac seal zone for elective EVAR

1.1 All health boards

1.2 Iliacs by Health Board

1.3 Iliacs by gender

1.4 Iliacs by year group

1.5 Left and right iliacs plotted separately

2 Limb occlusion

  • This section deals with limb occlusion after EVAR
  • The internal iliac artery component of an iliac branch device is not considered, only the external or common iliac arteries
  • The purposefully occluded side on AUI is discounted
  • For IBD, seal in EIA is assumed and so these are merged

2.1 Limb occlusions

2.1.1 Number of occlusions

  • Overall, 4.3% of limbs have occluded

2.1.2 Occlusion free survival

  • 94% of limb occlusions happen within 6 years

2.1.3 Number of occlusions - left vs right

2.1.4 Number of occlusions - iliac seal zone

2.1.5 Occlusion free survival - iliac seal zone

  • Occlusion rate for CIA seal = 4.2%
  • Occlusion rate for EIA seal = 4.8%

2.2 Health Board

2.2.1 Number of limb occlusions by site

  • GG & C limb occlusion rate = 5%
  • FV limb occlusion rate = 1.1%
  • Lothian limb occlusion rate = 0.9%

2.2.2 Limb occlusion survival by site

2.3 Gender

2.3.1 Number of limb occlusions - gender

2.3.2 Limb occlusion survival - gender

2.4 Year

2.4.1 Number and percentage of limb occlusions - year

2.4.2 Number and percentage of limb occlusions - year and health board

2.4.2.1 NHS Greater Glasgow & Clyde

  • 1471 limbs inserted
  • 74 occlusions (5%)

2.4.2.2 NHS Forth Valley

  • 91 limbs inserted
  • 1 occlusions (1.1%)

2.4.2.3 NHS Lothian

  • 235 limbs inserted
  • 2 occlusions (0.9%)

2.4.3 Number and percentage of limb occlusions - year and device

  • For this section, only select devices with at least one use since 2010 are presented

2.4.3.1 Endurant

  • 119 Endurant limbs inserted
  • 10 occlusions (8.4%)

2.4.3.2 Zenith

  • 202 Zenith limbs inserted
  • 6 occlusions (3%)

2.4.3.3 Anaconda

  • 624 Anaconda limbs inserted
  • 45 occlusions (7.2%)

2.4.3.4 Endurant II

  • 513 Endurant II limbs inserted
  • 7 occlusions (1.4%)

2.4.3.5 Excluder

  • 94 Excluder limbs inserted
  • 0 occlusions (0%)

2.5 Year Groups

  • In this section, data are presented in five year groups

2.5.1 Number of limb occlusions - year group

  • As there is currently only data for multiple year groups for GG&C health board, only GG&C limb occlusions are included here

2.5.2 Limb occlusion survival - year group

  • As there is currently only data for multiple year groups for GG&C health board, only GG&C limb occlusions are included here
## Warning: Removed 5 rows containing missing values (geom_path).

## Warning: Removed 5 rows containing missing values (geom_path).

2.6 Device

  • Only the same select devices are included here.

2.6.1 Number of limb occlusions - device

2.6.2 Occlusion free survival - device

3 Anaconda re-call

  • The Anaconda stent-graft was voluntarily withdrawn from the market in October 2013 before being re-introduced unchanged in March 2014
  • Limb occlusion rates in GG & C were above 5% in each of the five years before 2013
  • NHS GG & C was the major user of Anaconda
  • Occlusion rates are separated in the figures below into EVARs in 2013 and before (ie. before the Anaconda withdrawal) and those after
  • As other health booards had low numbers of Anaconda use, only GG & C data are used for these figures

3.1 Number of occluded limbs

  • Pre-recall, 6.6% of limbs occluded
  • Pre-recall, 2% of limbs have occluded

3.2 Limb occlusion survival

3.2.1 All devices, pre- and post-recall

## Warning: Removed 20 rows containing missing values (geom_path).
## Warning: Removed 19 rows containing missing values (geom_point).
## Warning: Removed 20 rows containing missing values (geom_path).
## Warning: Removed 19 rows containing missing values (geom_point).

3.2.2 Anaconda only, pre- and post-recall

3.2.3 All devices, post-recall

Home